top of page

Research Roundup: Nov 28, 2023

Best of cannabinoid science this week...

A clinical study shows that 50 milligrams CBD for eight weeks caused significant improvements in sleep quality & enhanced the functioning of natural killer immune cells Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity

In people undergoing chemotherapy cancer treatments, 600 milligrams of CBD per day helped to prevent neuropathy

Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy

In dogs with drug resistant epilepsy, 9 mg/kg/day of CBD effectively reduced seizures, though the liver enzyme activities should be monitored & side effects of decreased appetite & increased vomiting should be watched for The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study

On potential drug interactions of THC & CBD, though these “are probably of little importance at low or moderate doses” Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs: Recommendations for Clinical Practice

A special series of articles on PEA for neuroinflammation & pain Special Issue "To Go Where Nature Leads: Focus on Palmitoylethanolamide and Related ALIAmides As Innovative Approach to Neuroinflammatory and Pain-Related Disease States in Honor of Doctor Francesco Della Valle"

On the actions of PEA & OEA via regulation of genetic transcription Editorial: The paracannabinoid system: endocannabinoid-like lipids and their functions

A review of natural compounds that modulate the endocannabinoid system Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review

A great review of the gut-brain- endocannabinoid axis Neuro-Gastro-Cannabinology: A Novel Paradigm for Regulating Mood and Digestive Health

And a review of the history of cannabinoids for GI tract disorders & their future Pharmacohistory of Cannabis Use-A New Possibility in Future Drug Development for Gastrointestinal Diseases

For visceral pain, a review of using the non-intoxicating cannabinoids Non-Intoxicating Cannabinoids in Visceral Pain

In people with advanced cancer, a review of using cannabis to support their gut health Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges

A review of using cannabinoids for epilepsy & seizure disorders Cannabinoid treatments in epilepsy and seizure disorders

In a mouse model of psoriasis, using topical CBD significantly lowered psoriasis scores Cannabidiol-Loaded Lipid-Stabilized Nanoparticles Alleviate Psoriasis Severity in Mice: A New Approach for Improved Topical Drug Delivery

In heart tissue, CBD & THCV lowered inflammation Non-Psychoactive Phytocannabinoids Inhibit Inflammation-Related Changes of Human Coronary Artery Smooth Muscle and Endothelial Cells

In a rat model of hypertension from high blood pressure coming from the lungs, CBD lowered fibrosis (scarring) Cannabidiol alleviates right ventricular fibrosis by inhibiting the transforming growth factor β pathway in monocrotaline-induced pulmonary hypertension in rats

In a tissue model of intestinal inflammation, a number of cannabinoids lowered inflammation & altered genetic transcription, the strongest being THC Phytocannabinoids Reduce Inflammation of Primed Macrophages and Enteric Glial Cells: An In Vitro Study

In an animal model of Parkinson's disease, the terpene beta caryophyllene decrease neuro inflammation & protected the dopamine neurons via inhibition of the inflammasome β-Caryophyllene decreases neuroinflammation and exerts neuroprotection of dopaminergic neurons in a model of hemiparkinsonism through inhibition of the NLRP3 inflammasome

In a thesis project using two mouse models of schizophrenia, HU-580 (a stable version of CBDA) seemed to help via the CB1 & 5-HT1A serotonin receptor CANNABIDIOLIC ACID METHYL ESTER (HU-580) TREATMENT IN TWO PRECLINICAL MODELS OF SCHIZOPHRENIA: THE ROLE OF CB1 AND 5-HT1A RECEPTORS


bottom of page